Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03013582
Other study ID # 16D.538
Secondary ID
Status Not yet recruiting
Phase N/A
First received December 20, 2016
Last updated January 4, 2017
Start date January 2017

Study information

Verified date January 2017
Source Thomas Jefferson University
Contact Michael P Gaspar, MD
Email michaelpgaspar@gmail.com
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Tendon adhesions of the hand remain a ubiquitous problem facing hand surgeons and hand therapists alike. Despite their commonality, no consensus exists as to the best means of preventing adhesions, or the most ideal methods to treat them once they have occurred. The purpose of this study is to compare patient outcomes after standard operative tenolysis performed for adhesions of the hand to outcomes after tenolysis with the use of allograft human amniotic membrane.


Description:

Patients who are scheduled to undergo operative tenolysis of the flexor and/or extensor tendons of the hand will be recruited. Our target enrollment is 40 patients (20 control plus 20 experimental), based on the power analysis detailed in the next paragraph. Enrolled patients will be randomized to either standard operative tenolysis, or tenolysis with placement of AlloWrap. Randomization will be performed by computerized random number generator. All surgeries will be performed by one senior fellowship-trained hand surgeon. Baseline measurements of total active motion (TAM), passive range of motion (PROM), and survey scores of the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) and Patient Rated Wrist Evaluation (PRWE) will be recorded pre-operatively. In addition, patients' pain level will be assessed using the visual analog scale (VAS) both at rest, and during the examination. These same values will be re-evaluated at post-operative follow-up visits at 2 weeks, 1 month, 3 months and 6 months. PROM will also be evaluated intra-operatively by the surgeon, and documented.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date
Est. primary completion date July 2018
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All adult patients deemed candidates for operative tenolysis of the hand or wrist

- Age =18

Exclusion Criteria:

- Patients younger than 18 years at the time of surgery;

- Any patient who would not be able or willing to comply with the protocol or perform assessments;

- Patients with medical conditions that may preclude placement of human biological membrane;

- Patients who have previously undergone tenolysis on the operative hand;

- Patients that will have multiple surgeries that are deemed as possible confounders, particularly those requiring an additional incision;

- Is physically or mentally compromised (i.e. being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his or her ability to participate in the clinical study;

- Is a prisoner;

- Is a transient.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Biological:
Amnion Tendon Wrapping
Tendon is wrapped with the allograft
Procedure:
Surgical Tenolysis
Surgical release of peritendinous scarred tissue

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Thomas Jefferson University

References & Publications (8)

Branford OA, Lee DA, Bader DL, Grobbelaar AO. The mechanics of flexor tendon adhesions. J Hand Surg Eur Vol. 2012 Jul;37(6):555-63. doi: 10.1177/1753193411432675. — View Citation

Fairbairn NG, Randolph MA, Redmond RW. The clinical applications of human amnion in plastic surgery. J Plast Reconstr Aesthet Surg. 2014 May;67(5):662-75. doi: 10.1016/j.bjps.2014.01.031. Review. — View Citation

Gaspar MP, Abdelfattah HM, Welch IW, Vosbikian MM, Kane PM, Rekant MS. Recurrent cubital tunnel syndrome treated with revision neurolysis and amniotic membrane nerve wrapping. J Shoulder Elbow Surg. 2016 Dec;25(12):2057-2065. doi: 10.1016/j.jse.2016.09.013. — View Citation

Kohanzadeh S, Lugo L, Long JN. Safety of antiadhesion barriers in hand surgery. Ann Plast Surg. 2013 May;70(5):527-9. doi: 10.1097/SAP.0b013e31827eace2. — View Citation

Ozbölük S, Ozkan Y, Oztürk A, Gül N, Ozdemir RM, Yanik K. The effects of human amniotic membrane and periosteal autograft on tendon healing: experimental study in rabbits. J Hand Surg Eur Vol. 2010 May;35(4):262-8. doi: 10.1177/1753193409337961. — View Citation

Rouhani A, Tabrizi A, Ghavidel E. Effects of non-steroidal anti-inflammatory drugs on flexor tendon rehabilitation after repair. Arch Bone Jt Surg. 2013 Sep;1(1):28-30. — View Citation

Vucekovich K, Gallardo G, Fiala K. Rehabilitation after flexor tendon repair, reconstruction, and tenolysis. Hand Clin. 2005 May;21(2):257-65. Review. — View Citation

Wu YF, Tang JB. Apoptosis in adhesions and the adhesion-tendon gliding interface: relationship to adhesion-tendon gliding mechanics. J Hand Surg Am. 2013 Jun;38(6):1071-8. doi: 10.1016/j.jhsa.2013.03.012. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Total Active Motion (TAM) 6 months No
Primary Passive Range of Motion (PROM) 6 months No
Secondary Patient-Rated Wrist Evaluation (PRWE) Validated Outcome score/questionnaire specific to wrist function 6 months No
Secondary Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) Validated Outcome score/questionnaire generalized to upper extremity conditions 6 months No
Secondary Complications 2 weeks, One month, 3 months, 6 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05570058 - Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979417 - Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
Completed NCT02408744 - Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease Phase 1/Phase 2
Active, not recruiting NCT00148837 - Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis Phase 2
Recruiting NCT05661123 - Effect of Modified Complete Decongestive Therapy on Lower Limbs Fibrosis Post Cellulitis N/A
Recruiting NCT04795570 - Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors
Active, not recruiting NCT05075785 - Covid-19 Respiratory Sequelae French Cohort
Recruiting NCT03308916 - Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers N/A
Recruiting NCT05459259 - Physiotherapy for Arthrofibrosis Following Knee Replacement.
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT00001729 - Combination Drug Therapy for Patients With Hepatitis C Phase 3
Completed NCT02049307 - Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial Phase 2
Active, not recruiting NCT05685823 - The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle
Completed NCT00744939 - Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist Phase 4
Completed NCT00252642 - Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C N/A
Recruiting NCT04934202 - Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
Completed NCT02604862 - Imaging FIB ONE in the Human Lung Using Endomicroscopy Early Phase 1
Completed NCT02774161 - B-mode Ultrasound Imaging in Detecting Early Liver Cancer N/A
Active, not recruiting NCT01246388 - Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy N/A
Completed NCT02161952 - Pirfenidone, an Antifibrotic and Antiinflammatory Drug Phase 2